表紙
市場調查報告書

暈車藥的全球市場:2019年∼2023年

Global Motion Sickness Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 895012
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
暈車藥的全球市場:2019年∼2023年 Global Motion Sickness Drugs Market 2019-2023
出版日期: 2019年07月18日內容資訊: 英文 124 Pages
簡介

全球暈車藥市場主要使用可作為處方藥和非處方藥使用的仿製藥來實現。抗膽鹼能藥和抗組胺藥認為是抑制和預防暈動病相關症狀的一線療法。有幾種抗組胺藥可用作非處方藥,可供兒科患者使用。這些藥物OTC的可用性增加了其可及性和可負擔性,並為患者提供了自我藥物治療的自由用於治療輕微疾病相關症狀。此外,OTC藥物的可用性透過消除購買這些藥物的處方需要而減少了與藥物治療相關的經濟負擔。該店面銷售(OTC)的需求,預計成為全世界的暈車藥市場在預測期間內以約4%的年複合成長率擴大的要素之一。

本報告提供全球市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 抗膽鹼藥
  • 抗組織胺藥
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 噁心資訊技術的出現
  • 虛擬實境的增加趨勢
  • 心身病研究的發展

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Baxter International Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31733

About this market

Motion sickness drugs are pharmaceutical agents that are used to treat nausea and vomiting caused due to motion sickness. Technavio's motion sickness drugs market analysis considers sales from both anticholinergics and antihistamines. Our analysis also considers the sales of motion sickness drugs in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high demand for hyoscine hydrobromide or scopolamine for the prevention of motion sickness will play a significant role in the anticholinergics segment to maintain its market position. Also, our global motion sickness drugs market report also looks at factors such as availability of over-the-counter (OTC) drugs, availability of drugs in multiple dosage forms and growing tourism worldwide. However, nonpharmacological countermeasures to treat motion sickness, the launch of generics, side effects associated with motion sickness drugs may hamper the growth of the motion sickness drugs industry over the forecast period.

Overview

Availability of over-the-counter (OTC) drugs

The global motion sickness drugs market is predominantly served by the use of generic drugs that are available both as prescription and OTC drugs. Anticholinergics and antihistamines have been regarded as first-line therapy for suppressing and preventing the symptoms associated with motion sickness. Several antihistamines are available as OTC drugs and can be used by pediatric patients. The availability of these medicines OTC increases their accessibility and affordability and provides patients with the freedom of self-medication for the treatment of symptoms associated with minor illnesses. In addition, the availability of OTC drugs reduces the financial burden associated with medication treatment by eliminating the need for a prescription for the purchase of these drugs. This demand for over-the-counter (OTC) will lead to the expansion of the global motion sickness drugs market at a CAGR of almost 4% during the forecast period.

The advent of nauseogenic information technology

The nauseogenic information technology involves the use of nauseogenic vehicles that help in analyzing an individual's postural stability and can reveal the underlying neural or sensory-motor processes that help in achieving successful body stability. This technology revealed that motion sickness often occurs for a narrow band of frequencies of the imposed oscillation. The frequency band obtained in patients with motion sickness is similar to that produced by postural sway during the natural stance. Further advances in nauseogenic information technology are anticipated to have a positive impact on market growth.

For the detailed list of factors that will drive the global motion sickness drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global motion sickness drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading motion sickness drugs manufacturers, that include Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc.

Also, the motion sickness drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Anticholinergics - Market size and forecast 2018-2023
  • Antihistamines - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Advent of nauseogenic information technology
  • Rising trend of virtual reality
  • Growing research in psychosomatic disorders

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter International Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Anticholinergics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Anticholinergics - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Antihistamines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Antihistamines - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Dosage forms: An overview
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Baxter International Inc. - Vendor overview
  • Exhibit 50: Baxter International Inc. - Business segments
  • Exhibit 51: Baxter International Inc. - Organizational developments
  • Exhibit 52: Baxter International Inc. - Geographic focus
  • Exhibit 53: Baxter International Inc. - Segment focus
  • Exhibit 54: Baxter International Inc. - Key offerings
  • Exhibit 55: Baxter International Inc. - Key customers
  • Exhibit 56: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 57: GlaxoSmithKline Plc - Business segments
  • Exhibit 58: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 59: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 60: GlaxoSmithKline Plc - Segment focus
  • Exhibit 61: GlaxoSmithKline Plc - Key offerings
  • Exhibit 62: GlaxoSmithKline Plc - Key customers
  • Exhibit 63: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 64: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 65: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 66: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 67: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 68: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 69: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 70: Pfizer Inc. - Vendor overview
  • Exhibit 71: Pfizer Inc. - Business segments
  • Exhibit 72: Pfizer Inc. - Organizational developments
  • Exhibit 73: Pfizer Inc. - Geographic focus
  • Exhibit 74: Pfizer Inc. - Segment focus
  • Exhibit 75: Pfizer Inc. - Key offerings
  • Exhibit 76: Pfizer Inc. - Key customers
  • Exhibit 77: Prestige Consumer Healthcare Inc. - Vendor overview
  • Exhibit 78: Prestige Consumer Healthcare Inc. - Business segments
  • Exhibit 79: Prestige Consumer Healthcare Inc. - Organizational developments
  • Exhibit 80: Prestige Consumer Healthcare Inc. - Geographic focus
  • Exhibit 81: Prestige Consumer Healthcare Inc. - Segment focus
  • Exhibit 82: Prestige Consumer Healthcare Inc. - Key offerings
  • Exhibit 83: Prestige Consumer Healthcare Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors